亚太地区孕妇B族链球菌直肠阴道定植率及血清型分布的系统综述与荟萃分析(2014-2025)
该系统综述与荟萃分析检索2014年1月至2025年10月MEDLINE、Embase和PubMed数据库,纳入98项研究、978,150名孕妇,其中172,973名定植B族链球菌,合并定植率为18.0%(95% CI 12%-23%)。血清型III最为常见(范围5.0%-100.0%),β-内酰胺类耐药率低(0%-2.0%)。东南亚研究有限,需持续监测以指导防治。
要点
- 亚太地区孕妇GBS直肠阴道定植合并率为18.0%(95% CI 12%-23%)
- 血清型III最常见,报告范围为5.0%-100.0%
- β-内酰胺类耐药率低(0%-2.0%),但东南亚和太平洋地区数据有限
核心结论
- 亚太地区孕妇GBS定植常见,合并定植率为18.0%(95% CI 12%-23%)。
- 需持续监测GBS定植率,尤其太平洋和东南亚国家,以指导防治项目。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和PubMed数据库2014年1月至2025年10月发表的文章。
- 共识别1,623项研究,最终纳入98项进行荟萃分析。
- 纳入978,150名孕妇,其中172,973名定植GBS。
主要发现
- GBS合并定植率为18.0%(95% CI 12%-23%)。
- 24项研究报告血清型分布,血清型III最常见(范围5.0%-100.0%)。
- 东南亚地区研究有限。
临床怎么用
- 亚太地区孕妇GBS定植率较高,应重视产前GBS筛查与预防策略。
- β-内酰胺类耐药率低,提示其仍可作为GBS预防和治疗的可靠选择。
- 太平洋和东南亚国家需加强GBS监测以指导本地防治项目。
局限性
- 东南亚地区研究有限,可能影响区域代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a systematic review and meta-analysis of group B Streptococcus (GBS) rectovaginal colonization prevalence, serotype distribution, and antimicrobial drug resistance (AMR) rates among pregnant women in the Asia-Pacific region. We included articles published in the MEDLINE, Embase, and PubMed databases during January 2014-October 2025. Overall, 1,623 studies were identified; 98 of those were included in the meta-analysis. Of 978,150 pregnant women, 172,973 were colonized with GBS; pooled estimated prevalence was 18.0% (95% CI 12%-23%). Studies from Southeast Asia were limited. GBS serotype distributions were reported in 24 studies; serotype III was the most common (range 5.0%-100.0%). Thirty studies included AMR rates; low (0%-2.0%) AMR rates were found for β-lactams. GBS colonization is common among pregnant women in the Asia-Pacific region. Continued surveillance of GBS prevalence will be needed, particularly in Pacific and Southeast Asian countries, to guide effective GBS prevention and treatment programs.
引用
- Toh ZQ, Ha Do LA, Ong DS, et al. Systematic Review and Meta-analysis of Group B Streptococcus Rectovaginal Colonization Rates and Serotype Distribution among Pregnant Women, Asia-Pacific Region, 2014-2025. Emerg Infect Dis. 2026. PMID: 42811015. doi:10.3201/eid3210.260687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。